scholarly journals A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy

2017 ◽  
Vol 28 ◽  
pp. v351 ◽  
Author(s):  
A. Gonzalez Martin ◽  
L.A. Rojas ◽  
P.S. Braly ◽  
J. Barter ◽  
D.M. O'Malley ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Maintenance Treatment ◽  
Advanced Ovarian Cancer ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Multicenter Phase

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

2016 ◽  
Vol 17 (1) ◽  
pp. 78-89 ◽  
Author(s):  
Andreas du Bois ◽  
Gunnar Kristensen ◽  
Isabelle Ray-Coquard ◽  
Alexander Reuss ◽  
Sandro Pignata ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
First Line ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Line Chemotherapy

A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS5606-TPS5606 ◽  
Author(s):  
Antonio Gonzalez-Martin ◽  
Floor Jennishens Backes ◽  
Klaus H. Baumann ◽  
Dana Meredith Chase ◽  
Mathias Konrad Fehr ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Maintenance Treatment ◽  
Advanced Ovarian Cancer ◽  
Phase Iii ◽  
Front Line ◽  
Double Blind ◽  
Phase Iii Trial ◽  
Platinum Based Chemotherapy

ReTHINK: A randomized, double-blind, placebo-controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS7080-TPS7080 ◽  
Author(s):  
Francesco Passamonti ◽  
Jean-Jacques Kiladjian ◽  
Alessandro M. Vannucchi ◽  
Andreas Reiter ◽  
Savita Bharathy ◽  
...  
Keyword(s):  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Multicenter Phase
Sign in / Sign up

Export Citation Format

Share Document